Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments

Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.

Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development Mr. Shah, a Wall Street veteran with over 25 years of experience, brings broad leadership capabilities to Tevogen Bio.

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.

Tevogen Bio Announces Series A-1 Preferred Stock Investment The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.